This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 Mar;21(3):e133.

doi: 10.1016/S1470-2045(20)30089-9. Epub 2020 Feb 14.

Enfortumab vedotin shows promise in solid tumours

Talha Khan Burki

PMID: 32066546
DOI: 10.1016/S1470-2045(20)30089-9

Comment

Enfortumab vedotin shows promise in solid tumours

Talha Khan Burki. Lancet Oncol. 2020 Mar.

. 2020 Mar;21(3):e133.

doi: 10.1016/S1470-2045(20)30089-9. Epub 2020 Feb 14.

Author

Talha Khan Burki

PMID: 32066546
DOI: 10.1016/S1470-2045(20)30089-9

No abstract available

PubMed Disclaimer

Comment on

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Rosenberg JE, et al. J Clin Oncol. 2019 Oct 10;37(29):2592-2600. doi: 10.1200/JCO.19.01140. Epub 2019 Jul 29. J Clin Oncol. 2019. PMID: 31356140 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science